Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer

NCT00246571 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00246571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00246571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2006
Completion date
June 30, 2011
Enrollment
217 (actual)
Sites
113

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms